The diagnostic superiority of rADCmin (AUC = 0.81 for overall MGMT prediction, and 0.78 specifically in IDH-wildtype gliomas) stems from its unique attributes: ADCmin captures the most restricted diffusion regions corresponding to hypercellular tumor areas where MGMT methylation predominantly influences therapeutic response (13), while normalization to contralateral white matter (yielding rADCmin) mitigates scanner-induced variability. Here, MGMT is linked to glioma.